A randomized trial tested cognitive rehab for long COVID brain fog — here's what happened
Long COVID's cognitive symptoms have resisted every treatment tried so far — until a new randomized trial decided to test whether structured brain training could change that.
The results are in, and the picture is more complicated than a clean win.
🧠 The First Real Test of Cognitive Rehab for Long COVID
- A randomized clinical trial published in JAMA Network Open directly tested cognitive rehabilitation in patients with long COVID-related cognitive impairment — the first controlled evidence in a condition that has, until now, had no proven treatments.
- The study measured functional outcomes, not just symptom scores, putting real-world daily performance at the center of what counts as improvement.
- The catch: cognitive impairment in long COVID is heterogeneous, and what works for one patient profile may not transfer to another — the trial lands in a field still struggling to define who exactly needs what.
Why it matters: This is the first randomized evidence base for a cognitive intervention in long COVID. It doesn't close the question, but it moves the field from "we have nothing" to "we have a starting point."
Key Findings
🩸 Blood Clot Risk Doesn't End When Acute COVID Does
- A systematic review and meta-analysis found that thromboembolic events — blood clots in veins and arteries — are associated with post-COVID syndrome, not just the acute infection phase.
- The link suggests that the clotting risk some patients face extends well into the chronic illness period, with implications for how post-COVID patients are monitored and managed.
💊 Most Long COVID Patients Are Managing Symptoms Themselves
- A cross-sectional survey found that patients with long COVID are widely using over-the-counter medicines and non-prescribed therapies to manage their symptoms, driven by the absence of proven treatments and uneven access to care.
- The finding highlights a real-world gap: patients aren't waiting for clinical guidance — they're improvising, with unknown safety and efficacy consequences at scale.
🧬 A Genetic Clue to Brain Fog — With a Catch
- A study of 363 Brazilian healthcare professionals found that a specific genetic variant in the TMPRSS2 gene (rs2070788) was associated with brain fog in post-COVID patients, particularly in women and adults aged 18–29.
- The association only emerged in the symptomatic subgroup and in specific statistical models, making this a signal worth following rather than a confirmed mechanism.
🏥 "That's Not My Silo": How Fragmented Care Fails Long COVID Patients
- Qualitative research from the mid-Atlantic U.S. found that long COVID patients frequently bounce between multiple specialists whose narrow focus leaves no one coordinating the full picture.
- Patients described a system structurally mismatched to a multi-organ illness — specialists who each addressed one symptom while the underlying condition went unmanaged as a whole.
🚶 How Far Can Long COVID Patients Walk? It Depends on More Than COVID
- A multicenter Italian study of 686 long COVID patients found that 6-minute walk distance was shaped by sex, pre-existing conditions, COVID severity, and specific persisting symptoms like dyspnea and depressed mood — with some spontaneous improvement over time at roughly 2.6 meters per month elapsed.
- Conditions like atrial fibrillation, chronic lung disease, and renal failure each reduced walking distance by 26–87 meters, underscoring that exercise capacity in long COVID is a layered problem.
👶 Reinfection May Be Pushing Long COVID Higher in Kids
- A primary care study found that SARS-CoV-2 reinfection was a potential contributing factor to long COVID in children and adolescents, adding to a picture of pediatric long COVID that has been muddied by wide variation in how studies define and measure it.
- A separate overview of reviews confirmed that methodological inconsistency — not just biology — is driving the wildly different prevalence estimates reported across pediatric long COVID research.
Implications
Long COVID research is generating signals faster than it can standardize them — from genetic variants in brain fog to clotting risk that outlasts acute illness. The unresolved tension: without agreed biomarkers or patient stratification criteria, even a promising intervention like cognitive rehabilitation risks being tested on the wrong people for the wrong reasons.
Studies in this issue
Primary sources used for this newsletter.
- Cognitive Training and Daily Function in People with Long COVID Memory and Thinking Problems: A Randomized Trialmain storyJAMA network open2026-07-01PMID 42384384
- Blood Clot Risks Linked to Long COVID: A Review and Analysiskey findingFrontiers in cardiovascular medicine2026-06-29PMID 42368852
- Challenges in Coordinating Long COVID Care Across Different Health Providers in the Mid-Atlantic U.S.key findingSSM. Qualitative research in health2026-06-29PMID 42367370
- Link between genetic differences in TMPRSS2 and Long COVID in Brazilian healthcare workerskey findingFrontiers in cellular and infection microbiology2026-06-30PMID 42376321
- Factors linked to 6-minute walk test performance in people with long COVID in Italykey findingInternal and emergency medicine2026-06-30PMID 42377750
- Repeated COVID-19 infections may contribute to long COVID in children and teenskey findingFrontiers in pediatrics2026-07-01PMID 42382648
- How People Manage Long COVID Symptoms Using Over-the-Counter Medicines and Other Home Treatmentskey findingBMC public health2026-07-03PMID 42393618
Continue reading
All Long Covid issuesGet the next Long Covid issue
Seven papers, once a week. Free.